Selective,highaffinity5-HT1Areceptorantagonist(Ki=0.6nMinvitro).Enhancestheactionofselective5-HTreuptakeinhibitorsandreversescitalopram-induced(Cat.No.1427)inhibitionofSEROtonergiccellfiring.
SoldforresearchpurposesunderagreementfromAstraZeneca
NAD299hydrochlorideisalsoofferedaspartoftheTocriscreenPlus.FindoutmoreaboutcompoundlibrariesavailablefromTocris.
M.Wt | 354.85 |
Formula | C18H23FN2O2.HCl |
Storage | DesiccateatRT |
Purity | ≥98%(HPLC) |
CASNumber | 184674-99-5 |
PubChemID | 90488823 |
InChIKey | GSZJANKLCPHEEX-BTQNPOSSSA-N |
Smiles | FC1=C2C(C[C@@H](N(C4CCC4)C3CCC3)CO2)=C(C(N)=O)C=C1.Cl |
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
Solvent | MaxConc.mg/mL | MaxConc.mM | |
---|---|---|---|
Solubility | |||
DMSO | 35.48 | 100 | |
water | 35.48 | 100 |
Thefollowingdataisbasedontheproductmolecularweight354.85.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.
Concentration/SolventVolume/Mass | 1mg | 5mg | 10mg |
---|---|---|---|
1mM | 2.82mL | 14.09mL | 28.18mL |
5mM | 0.56mL | 2.82mL | 5.64mL |
10mM | 0.28mL | 1.41mL | 2.82mL |
50mM | 0.06mL | 0.28mL | 0.56mL |